OLIPASS Corporation

KOSDAQ:A244460 Stock Report

Market Cap: ₩26.5b

OLIPASS Past Earnings Performance

Past criteria checks 0/6

OLIPASS has been growing earnings at an average annual rate of 33.8%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 190.7% per year.

Key information

33.8%

Earnings growth rate

34.7%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate190.7%
Return on equity-503.1%
Net Margin-318.4%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

What Kind Of Investors Own Most Of OLIPASS Corporation (KOSDAQ:244460)?

Feb 24
What Kind Of Investors Own Most Of OLIPASS Corporation (KOSDAQ:244460)?

Should OLIPASS (KOSDAQ:244460) Be Disappointed With Their 21% Profit?

Jan 02
Should OLIPASS (KOSDAQ:244460) Be Disappointed With Their 21% Profit?

Revenue & Expenses Breakdown

How OLIPASS makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A244460 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 235,251-16,7175,96314,005
30 Jun 233,635-18,9526,58513,875
31 Mar 232,128-23,3817,52615,649
31 Dec 222,296-24,1688,99815,030
30 Sep 221,806-25,2439,85814,914
30 Jun 221,782-25,76010,32214,941
31 Mar 221,683-24,29610,33113,391
31 Dec 21852-25,1359,32914,347
30 Sep 21856-22,9088,85713,500
30 Jun 21893-23,0368,07614,182
31 Mar 211,539-24,8808,98114,886
31 Dec 202,861-24,18310,42313,127
30 Sep 203,512-47,85212,04412,173
30 Jun 203,614-50,24913,18711,282
31 Mar 202,993-46,85012,2499,752
31 Dec 191,705-45,64010,9429,693
30 Sep 191,019-25,6639,62510,062
30 Jun 19807-22,4128,8909,457
31 Mar 19666-27,0668,6209,586
31 Dec 18488-27,0497,8439,461
30 Sep 182675,5707,08811,896
30 Jun 182678,0686,18410,472
31 Mar 1819114,7165,5019,057
31 Dec 1711217,1074,8097,737
30 Sep 17139-9,2694,0633,394
30 Jun 1739-9,2775,2932,614
31 Mar 178-9,8405,0382,852
31 Dec 162-9,5763,5493,809
31 Dec 151,566-4,6482,7562,972
31 Dec 146,8173,1011,2831,372

Quality Earnings: A244460 is currently unprofitable.

Growing Profit Margin: A244460 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A244460's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare A244460's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A244460 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A244460 has a negative Return on Equity (-503.14%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 16:23
End of Day Share Price 2024/12/20 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OLIPASS Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehee KimMirae Asset Securities Co., Ltd.
Keunhee SeoSamsung Securities Co. Ltd.